Open Access

Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma

  • Authors:
    • Ji Hoon Kim
    • Young Hoon Kim
    • Hee-Chul Nam
    • Chang-Wook Kim
    • Jae-Sung Yoo
    • Ji Won Han
    • Jeong Won Jang
    • Jong Young Choi
    • Seung Kew Yoon
    • Ho Jong Chun
    • Jung Suk Oh
    • Suho Kim
    • Sung Hak Lee
    • Pil Soo Sung
  • View Affiliations

  • Published online on: June 21, 2024     https://doi.org/10.3892/ol.2024.14521
  • Article Number: 388
  • Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Atezolizumab/bevacizumab is the first line of treatment for unresectable hepatocellular carcinoma (HCC), combining immune checkpoint inhibitor and anti‑VEGF monoclonal antibodies. Hepatic arterial infusion chemotherapy (HAIC) is administered when the above‑described combination fails to confer sufficient clinical benefit. The present study aimed to explore the association between tumor programmed cell death‑ligand 1 (PD‑L1) positivity and HAIC response. A total of 40 patients with HCC who had undergone HAIC with available biopsy samples obtained between January 2020 and May 2023 were retrospectively enrolled. Tumor response, progression‑free survival (PFS), disease control rate (DCR) and overall survival (OS) were evaluated. PD‑L1 expression in tumor samples was assessed using a combined positivity score. The response rates of HAIC‑treated patients with advanced HCC after failure of atezolizumab/bevacizumab combination therapy were recorded. OS (P=0.9717) and PFS (P=0.4194) did not differ between patients with and without PD‑L1 positivity. The objective response rate (P=0.7830) and DCR (P=0.7020) also did not differ based on PD‑L1 status. In conclusion, the current findings highlight the consistent efficacy of HAIC, regardless of PD‑L1 positivity.
View Figures
View References

Related Articles

Journal Cover

August-2024
Volume 28 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kim JH, Kim YH, Nam H, Kim C, Yoo J, Han JW, Jang JW, Choi JY, Yoon SK, Chun H, Chun H, et al: Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma. Oncol Lett 28: 388, 2024
APA
Kim, J.H., Kim, Y.H., Nam, H., Kim, C., Yoo, J., Han, J.W. ... Sung, P.S. (2024). Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma. Oncology Letters, 28, 388. https://doi.org/10.3892/ol.2024.14521
MLA
Kim, J. H., Kim, Y. H., Nam, H., Kim, C., Yoo, J., Han, J. W., Jang, J. W., Choi, J. Y., Yoon, S. K., Chun, H., Oh, J. S., Kim, S., Lee, S. H., Sung, P. S."Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma". Oncology Letters 28.2 (2024): 388.
Chicago
Kim, J. H., Kim, Y. H., Nam, H., Kim, C., Yoo, J., Han, J. W., Jang, J. W., Choi, J. Y., Yoon, S. K., Chun, H., Oh, J. S., Kim, S., Lee, S. H., Sung, P. S."Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma". Oncology Letters 28, no. 2 (2024): 388. https://doi.org/10.3892/ol.2024.14521